• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Glaxo Share Price

    Glaxosmithkline Pharmaceuticals Share PriceGlaxoSmithKline Pharmaceuticals

    Large Cap 8k Result
    ₹1,678.15
    21.05 (1.27%)
    • Advice
    • Hold
    As on 02 December, 2023 | 08:09 BSE: 500660 NSE: GLAXOISIN: INE159A01016

    Glaxosmithkline Pharmaceuticals Performance

    Day Range

    • Low 1,669.95
    • High 1,708.00
    ₹ 1,678.15

    52 Week Range

    • Low 1,227.00
    • High 1,727.00
    ₹ 1,678.15
    • Open Price1,670.00
    • Previous Close1,657.10
    • Volume215618

    Start SIP in GlaxoSmithKline Pharmaceuticals

    Start SIP

    Glaxosmithkline Pharmaceuticals Share Price

    • Over 1 Month 19.28%
    • Over 3 Month 16.68%
    • Over 6 Month 26.44%
    • Over 1 Year 27.21%

    Glaxosmithkline Pharmaceuticals Key Statistics

    P/E Ratio 43.9
    PEG Ratio -0.7
    Market Cap Cr 28,429
    Price to Book Ratio 16.3
    EPS 34.6
    Dividend 1.9
    Relative Strength Index 68.94
    Money Flow Index 78.81
    MACD Signal 40.09
    Average True Range 53.21

    Glaxosmithkline Pharmaceuticals Investment Rating

    • Master Rating:

    • Glaxosmithkline Pharms. has an operating revenue of Rs. 3,308.40 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 26% is great, ROE of 35% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 18% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 84 which is a GOOD score indicating consistency in earnings, a RS Rating of 54 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    GlaxoSmithKline Pharmaceuticals Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 953738782799906729792
    Operating Expenses Qtr Cr 667597615571649582619
    Operating Profit Qtr Cr 287141167228257148173
    Depreciation Qtr Cr 18161716161615
    Interest Qtr Cr 0010010
    Tax Qtr Cr 814856606944262
    Net Profit Qtr Cr 2161311311641941191,218
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 3,3183,294
    Operating Expenses Annual Cr 2,4172,462
    Operating Profit Annual in Cr 799756
    Depreciation Cr 6668
    Interest Annual Cr 22
    Tax Annual Cr 228397
    Net Profit Annual Cr 6081,691
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 488820
    Cash from Investing Activity Annual Cr 805-420
    Cash from Financing Annual Activity Cr -1,544-524
    Net Cash Flow Annual Cr -251-124
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 1,7532,678
    Fixed Assets Annual Cr 350361
    Total Non Current Assets Annual Cr 861952
    Total Current Assets Annual Cr 2,4673,671
    Total Assets Annual Cr 3,3284,623
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 103158
    ROE Annual % 3563
    ROCE Annual % 4226
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2826
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 957762787802917745810
    Operating Expenses Qtr Cr 668618618574660596634
    Operating Profit Qtr Cr 289144170229257149175
    Depreciation Qtr Cr 18161716161615
    Interest Qtr Cr 0010010
    Tax Qtr Cr 824957606944263
    Net Profit Qtr Cr 2181321331651931191,219
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 3,3523,354
    Operating Expenses Annual Cr 2,4472,516
    Operating Profit Annual in Cr 804762
    Depreciation Cr 6668
    Interest Annual Cr 22
    Tax Annual Cr 229398
    Net Profit Annual Cr 6171,695
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 484811
    Cash from Investing Activity Annual Cr 808-406
    Cash from Financing Annual Activity Cr -1,543-524
    Net Cash Flow Annual Cr -251-119
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 1,7412,663
    Fixed Assets Annual Cr 350361
    Total Non Current Assets Annual Cr 832925
    Total Current Assets Annual Cr 2,4943,708
    Total Assets Annual Cr 3,3274,633
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 103157
    ROE Annual % 3564
    ROCE Annual % 4226
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2826
    Invest in Glaxosmithkline Pharmaceuticals

    Glaxosmithkline Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹1,678.15
    21.05 (1.27%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹1,591.13
    • 50 Day
    • ₹1,535.75
    • 100 Day
    • ₹1,488.82
    • 200 Day
    • ₹1,443.36
    • 20 Day
    • ₹1,561.96
    • 50 Day
    • ₹1,531.48
    • 100 Day
    • ₹1,479.28
    • 200 Day
    • ₹1,396.05

    Glaxosmithkline Pharmaceuticals Resistance and Support

    PIVOT
    ₹1,685.37
    Resistance
    First Resistance 1,700.78
    Second Resistance 1,723.42
    Third Resistance 1,738.83
    RSI 68.94
    MFI 78.81
    MACD Single Line 40.09
    MACD 50.42
    Support
    First Resistance 1,662.73
    Second Resistance 1,647.32
    Third Resistance 1,624.68

    Glaxosmithkline Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 222,103 13,905,869 62.61
    Week 206,419 12,562,660 60.86
    1 Month 222,897 14,071,494 63.13
    6 Month 107,714 7,042,354 65.38

    Glaxosmithkline Pharmaceuticals Result Highlights

    GlaxoSmithKline Pharmaceuticals Synopsis

    NSE-Medical-Diversified

    Glaxosmithkline Phar is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 3216.34 Cr. and Equity Capital is Rs. 169.41 Cr. for the Year ended 31/03/2023. GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1924PLC001151 and registration number is 001151.
    Market Cap 28,429
    Sales 3,273
    Shares in Float 4.24
    No of funds 196
    Yield 1.91
    Book Value 16.22
    U/D Vol ratio 1.3
    LTDebt / Equity
    Alpha 0.08
    Beta 0.34

    GlaxoSmithKline Pharmaceuticals

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 75%75%75%75%
    Mutual Funds 4.81%4.25%3.96%4.12%
    Insurance Companies 5.15%5.97%6.29%6.1%
    Foreign Portfolio Investors 2.5%2.41%2.28%2.28%
    Financial Institutions/ Banks 0.01%0.01%0.01%0.01%
    Individual Investors 10.62%10.57%10.54%10.56%
    Others 1.91%1.79%1.92%1.93%

    GlaxoSmithKline Pharmaceuticals Management

    Name Designation
    Ms. R S Karnad Chairperson
    Mr. B Akshikar Managing Director
    Dr.(Ms.) S Maheshwari Director
    Mr. S Williams Director
    Mr. P V Bhide Director
    Mr. A N Roy Director
    Mr. D Sundaram Director
    Mr. M Anand Director
    Mr. J Chandy Director

    Glaxosmithkline Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Glaxosmithkline Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2023-11-09 Quarterly Results
    2023-07-26 Quarterly Results
    2023-05-17 Audited Results & Final Dividend
    2023-02-07 Quarterly Results
    2022-11-11 Quarterly Results
    Date Purpose Remarks
    2023-06-30 FINAL Rs.32.00 per share(320%)Final Dividend
    2022-07-08 FINAL Rs.30.00 per share(300%)Dividend
    2022-07-08 SPECIAL Rs.60.00 per share(600%)Special Dividend
    2021-07-20 FINAL Rs.30.00 per share(300%)Dividend

    GlaxoSmithKline Pharmaceuticals MF Shareholding

    Name Amount(cr)
    ICICI Prudential Bluechip Fund Growth 41,269
    Nippon India Small Cap Fund - Growth 37,319
    ICICI Prudential Value Discovery Fund Growth 32,494
    ICICI Prudential Multi-Asset Fund Growth 24,931
    Nippon India Growth Fund - Growth 19,082

    GlaxoSmithKline Pharmaceuticals FAQs

    What is Share Price of GlaxoSmithKline Pharmaceuticals ?

    GlaxoSmithKline Pharmaceuticals share price is ₹1,678 As on 02 December, 2023 | 07:55

    What is the Market Cap of GlaxoSmithKline Pharmaceuticals ?

    The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹28428.9 Cr As on 02 December, 2023 | 07:55

    What is the P/E ratio of GlaxoSmithKline Pharmaceuticals ?

    The P/E ratio of GlaxoSmithKline Pharmaceuticals is 43.9 As on 02 December, 2023 | 07:55

    What is the PB ratio of GlaxoSmithKline Pharmaceuticals ?

    The PB ratio of GlaxoSmithKline Pharmaceuticals is 16.3 As on 02 December, 2023 | 07:55

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.